Ofatumumab

WikiDoc Resources for Ofatumumab
Articles
Most recent articles on Ofatumumab Most cited articles on Ofatumumab Review articles on Ofatumumab Articles on Ofatumumab in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ofatumumab Images of Ofatumumab Photos of Ofatumumab Podcasts & MP3s on Ofatumumab Videos on Ofatumumab
Evidence Based Medicine
Cochrane Collaboration on Ofatumumab Bandolier on Ofatumumab TRIP on Ofatumumab
Clinical Trials
Ongoing Trials on Ofatumumab at Clinical Trials.gov Trial results on Ofatumumab Clinical Trials on Ofatumumab at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ofatumumab NICE Guidance on Ofatumumab NHS PRODIGY Guidance FDA on Ofatumumab CDC on Ofatumumab
Books
Books on Ofatumumab
News
Ofatumumab in the news Be alerted to news on Ofatumumab News trends on Ofatumumab
Commentary
Blogs on Ofatumumab
Definitions
Definitions of Ofatumumab
Patient Resources / Community
Patient resources on Ofatumumab Discussion groups on Ofatumumab Patient Handouts on Ofatumumab Directions to Hospitals Treating Ofatumumab Risk calculators and risk factors for Ofatumumab
Healthcare Provider Resources
Symptoms of Ofatumumab Causes & Risk Factors for Ofatumumab Diagnostic studies for Ofatumumab Treatment of Ofatumumab
Continuing Medical Education (CME)
CME Programs on Ofatumumab
International
Ofatumumab en Espanol Ofatumumab en Francais
Business
Ofatumumab in the Marketplace Patents on Ofatumumab
Experimental / Informatics
List of terms related to Ofatumumab

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Ofatumumab is a human monoclonal antibody and which it is used to treat cancer. It is currently in a phase 3 dosage trial to assess it's effect in patients with relapsed follicular non-Hodgkin's lymphoma.